Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7927300 | 0.93 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL1538445 | 0.91 | NOS3 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL8181846 | 0.86 | NOS3 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL8776356 | 0.77 | — | — | |
| SCHEMBL7989296 | 0.77 | — | — | |
| SCHEMBL487176 | 0.75 | — | — | |
| SCHEMBL2178273 | 0.74 | — | — | |
| SCHEMBL486816 | 0.73 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL7541798 | 0.71 | NOS1 (0.44) | NOS3NOS1NOS2 | |
| SCHEMBL1032367 | 0.70 | CA1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-07-27 | — | — | US | disclosed |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-10537652-B2 | Cyclic urea compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2020-01-21 | — | — | US | disclosed |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20190151484-A2 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2785183-B1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-1993021169-A1 | BENZOTHIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021168-A1 | THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| US-5132319-A | Antiasthmatic, antiinflammatory, antiallergen and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-07-21 | — | — | US | disclosed |
| US-5128364-A | Antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-07-07 | — | — | US | disclosed |
| US-5093356-A | Antiallergens, antiasthma, antiinflammatory, cytoprotective | MERCK FROSST CANADA, INC. (CA) | 1992-03-03 | — | — | US | disclosed |
| US-5036067-A | Enzyme inhibotors | MERCK & CO., INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | GZMB, DNASE1L3, DNASE1 | NOS3 2025/4885NOS1 2543/4885NOS2 2212/4885 |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | NOS3 2025/4885NOS1 2543/4885NOS2 2212/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | NOS3 950/4885NOS1 1070/4885NOS2 726/4885 |
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | GZMB, SERPINB1, CTSB | NOS3 1561/4885NOS1 1187/4885NOS2 1318/4885 |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | GZMB, CTSB, SERPINB1 | NOS3 1252/4885NOS1 1017/4885NOS2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.